



Novelion Therapeutics Inc.
Investor Relations Department
887 Great Northern Way, Suite 250
Vancouver V5T 4T5
Canada

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: NVLN

Last Trade:	3.51
Trade Time:	4:00 PM ET Dec 11, 2017
Change:	-0.13 (-3.571%)
Day Range	3.48 - 3.88
52-Week Range	3.25 - 12.12
Volume	94,387

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 4, 2017*
[Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer](#)
- Nov 21, 2017*
[Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice](#)
- Nov 9, 2017*
[Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change](#)
- Oct 31, 2017*
[Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer](#)
- Oct 12, 2017*
[Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D](#)

Financials [\[View all \]](#)

- Mar 30, 2017*
[Annual Report \(10-K\)](#)
- May 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)